PubRank

Frank Hulstaert

Author PubWeight™ 23.02‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008 2.00
2 Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002 1.81
3 A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003 1.73
4 Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem 2004 1.53
5 Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006 1.15
6 Transcatheter aortic valve implantation (TAVI): risky and costly. BMJ 2012 1.14
7 Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ 2013 1.12
8 Critical assessment of belgian reimbursement dossiers of orphan drugs. Pharmacoeconomics 2011 1.09
9 A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 2004 0.98
10 Evaluation of INNO-LIA syphilis assay as a confirmatory test for syphilis. J Clin Microbiol 2002 0.93
11 Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 2008 0.92
12 Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009 0.90
13 Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. Hum Vaccin 2005 0.89
14 Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine 2011 0.83
15 Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions. AIDS 2003 0.82
16 Valorising and creating access to innovative medicines in the European union. Front Pharmacol 2011 0.81
17 Stereotactic body radiotherapy for lung cancer: how much does it really cost? J Thorac Oncol 2015 0.80
18 Market introduction of innovative high risk medical devices: towards a recast of the directive concerning medical devices. Eur J Health Law 2011 0.78
19 Performance characteristics of updated INNO-LiPA assays for molecular typing of human leukocyte antigen A (HLA-A), HLA-B, and HLA-DQB1 alleles. Clin Diagn Lab Immunol 2004 0.78
20 Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU. J Comp Eff Res 2012 0.76
21 Stimulating pharmaceutical innovation in the EU. Expert Rev Pharmacoecon Outcomes Res 2011 0.76
22 How many CIN2+ lesions can be avoided through HPV 16/18 vaccination? Acta Obstet Gynecol Scand 2009 0.75
23 Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system. J Clin Virol 2004 0.75